Re-reading Albert M. Kligman's 1969 Sole-Inventor 'Acne Treatment' Patent US3729568 Through the Holmesburg Prison Ethics Issue and the Origin of the Term 'Cosmeceutical'

About this memo: "Memos" in this series record candidate summaries at the stage where the primary source URL has been confirmed. We have retrieved Claim 1, inventor, filing/grant dates, and assignee from Google Patents, but the full specification body (detailed Examples, Holmesburg Prison clinical trial documents, FDA approval application materials) remains unread. We list only confirmed facts and explicitly mark speculation.

Why Excavate

Tretinoin (vitamin A acid, all-trans retinoic acid) is currently active as: (a) prescription acne treatment, (b) the only FDA-approved photoaging treatment, (c) acute promyelocytic leukemia (APL) differentiation therapy (oral), (d) a core ingredient in dermatology / aesthetic clinic in-house prescriptions. The starting point is the September 23, 1969 filing by Albert M. Kligman, US3729568 — the subject of this memo. The excavation's significance: (1) primary-source correction of DB "Kligman/J.E. Fulton co-invented" (incorrect), (2) the institutional history where Kligman's 1984 coinage "cosmeceutical" blurred the FDA cosmetic-vs-drug boundary, (3) the Holmesburg Prison clinical trial ethics issue, (4) excavating "drug-leaning cosmetics" as a separate axis from the Cosmetic Archaeology subseries (Kao / L'Oréal / Nivea sensitive-skin & redness axis), positioning this as the inaugural Week 4 "Cosmetic Patent" subseries episode.

Note: This memo does not state any drug-like efficacy claims like "tretinoin works on rosacea" or "cures." Following the Cosmetic Archaeology D-zone health/safety rules, we restrict ourselves to structural commentary on the patent.

Patent Basic Info

• Patent number: US3729568
• Title: Acne treatment
• Filing date: 1969-09-23
• Grant date: 1973-04-24
• Expiration: 1990-04-24 (Expired - Lifetime)
• Inventor: Albert M. Kligman (sole)
• Original assignee: Johnson & Johnson (New Brunswick, NJ)
• Current assignee: Johnson & Johnson
• Primary source: Google Patents (URL confirmed, Claim 1 retrieved)

Claim 1 (Verbatim)

The method of treating acne comprising applying vitamin A acid topically to the affected area in a concentration effective for the treatment of acne and repeating such applications daily, whereby said applications result in the peeling and diffuse redness of the skin treated, and continuing said treatment until the acne has subsided.

Four claim elements:

1. Topical application to the affected area
2. Vitamin A acid (= retinoic acid) at a concentration effective for treating acne
3. Daily repeated applications
4. Resulting in peeling and diffuse redness of treated skin, continuing until acne subsides

Design core: "covering the treatment protocol as a method patent." Vitamin A acid itself was already known by the 1900s, so a substance patent was unavailable; the design covers a treatment method combining specific usage / concentration / duration. This becomes the basis for the later Renova (photoaging indication) approval.

Abstract (Verbatim)

THE DERMATOLOGIC DISORDER CALLED ACNE VULGARIS IS CONTROLLED BY TOPICAL APPLICATION OF VITAMIN A ACID TO THE AFFECTED AREA. THE APPLICATION IS MADE DAILY WITH A COMPOSITION OF LOW VITAMIN A ACID CONTENT IN THE ORDER OF ABOUT 0.1%, BY WEIGHT, UNTIL THE ACNE IS RELIEVED. PARTICULARLY SUITABLE COMPOSITIONS FOR TOPICAL APPLICATIONS ARE ALSO PROVIDED.

A 0.1% w/w concentration is specified as standard.

DB Corrections — 2 Items (feedback_db_meta_verify_primary)

Continuing the Day 8~15 "19-correction series," this patent also produced corrections:

1. Inventorship: DB "Albert M. Kligman (co-invented with J.E. Fulton)" → primary source shows Kligman alone. J.E. Fulton was a clinical co-researcher and a co-author on papers, but absent from the patent inventorship.
2. Assignee: While DB does not explicitly suggest "University of Pennsylvania," general lore sometimes claims "UPenn held it and licensed to J&J." However, Google Patents lists the Original Assignee as Johnson & Johnson itself. This requires secondary verification, but for this memo we follow Google Patents' display.

DB corrections: 19 in Day 8~15 + 2 in Day 16 = total 21. Match-confirmed cases remain at 6.

Holmesburg Prison Clinical Trials (Ethics Issue)

From 1951 to 1974, Kligman conducted many clinical trials using inmates of Holmesburg Prison (a suburb of Philadelphia) as subjects. Trials included chemical-warfare tests (US Army contract), radiation tests (AEC contract), and multiple drug trials, with retinoic acid acne trials likely conducted at Holmesburg (primary-source verification required). Subjects were largely African-American and low-income, and informed consent did not meet current standards. Trials ended in 1974. The University of Pennsylvania did not issue a formal critical statement against Kligman in 1981, but in 2021 UPenn decided to remove buildings and funds named after Kligman (primary verification required, sourced via Wikipedia).

This memo records this ethics issue as fact only and does not pass moral judgment (AI Archaeology's problem framing is "re-read primary sources," not ethical adjudication).

FDA Approval Background (with Speculation)

Note: DB "unconfirmed" column says "1986 NEJM paper," but the actual journal was J Am Acad Dermatol (PubMed PMID: 3771853), not NEJM. This is another DB correction.

Cosmeceutical Coinage and FDA Boundaries

Kligman coined "cosmeceutical" (cosmetic + pharmaceutical) in 1984 to conceptualize the intermediate region between cosmetics and drugs. FDA does not legally recognize this category:

• FDA classification: Under the FD&C Act, cosmetic vs. drug is distinguished by "intended use" and whether the product changes "structure/function"
• Tretinoin treatment: Because it changes structure/function, it is treated as a drug; prescription-only in the US
• Japan PMDA treatment: Drug status, prohibited from cosmetic and quasi-drug formulation (only available via personal import)
• Cosmeceutical critique: FDA's position as of 2024 still holds that "cosmeceutical is a legally undefined marketing term"

The Cosmetic Archaeology subseries (Kao / L'Oréal / Nivea sensitive-skin & redness axis) differs in axis; this memo handles "the boundary of drug-leaning cosmetics." Following Cosmetic Archaeology D-zone health/safety rules, we restrict ourselves to structural commentary on the patent.

Contemporary Connection Hypothesis (Speculation)

No row reaches "identity." Calling this patent the "direct ancestor" of contemporary photoaging treatment is wrong as a method-patent scope claim — modern photoaging treatments include tretinoin's lineage but also a separate retinoid lineage (retinol / retinaldehyde / adapalene / tazarotene). This patent's significance is its position as an important precursor that covered the retinoid treatment protocol as a method patent.

Unconfirmed

• Specification body (detailed Examples) not read in this episode
• Primary verification of retinoic acid trials at Holmesburg (trial protocol, subject count, result reports) not retrieved
• 1971 FDA Retin-A first-approval primary (FDA approval letter) not retrieved
• 1995 Renova FDA first-approval year primary (FDA approval letter) not verified
• Original Assignee "Johnson & Johnson" direct receipt vs. UPenn license route requires further verification

Next Actions

• Future Note upgrade candidate: retrieve Renova 1995 approval document and expand to "Cosmetic Patent Note"
• Reflect 2 DB corrections (CS-001 inventor, 1986 paper journal) in ~/ai-archaeology/db/candidates.tsv CS-001 row
• Consider adding differentiation axis to project_cosmetic_archaeology.md (drug-leaning cosmetics excavation axis)

References:

• Google Patents: US3729568
• Wikipedia: Albert Kligman
• Wikipedia: Tretinoin
• Penn Center for the Book: Retin-A
• 40 Years of Topical Tretinoin Use in Review (JDDonline)
• Kligman et al. 1986, J Am Acad Dermatol (PubMed PMID 3771853)
• FDA: Is It a Cosmetic, a Drug, or Both?
• Cosmeceuticals - StatPearls NCBI